Primary risk
Primary risk: respiratory depression
Combination can be fatal; naloxone may be life-saving in opioid overdose.
SuspectedLaden…
N-Phenethyl-Noroxymorphone (PHM) is a synthetic morphinan derivative with a preclinically described potent mu-opioid receptor agonist profile. The N-phenethyl substitution pattern (known from NFEPP and related compounds) is associated with enhanced μ-receptor affinity — no human pharmacological validation exists. Human pharmacokinetics, clinical toxicity, bioavailability, and therapeutic index are entirely unestablished. The risk profile is consistent with an unknown potent opioid compound: respiratory depression is the primary risk, overdose danger exists at completely undefined potency thresholds, and dependence potential is rapid. Combination with other CNS/respiratory depressants — benzodiazepines, alcohol, GHB/GBL/1,4-BDO, pregabalin/gabapentin, other opioids, potent sedatives — substantially increases the risk of fatal respiratory arrest through additive CNS suppression and should be considered unacceptable risk. Community reports from RC contexts are monitoring signals only, not validated safety data. In an emergency, naloxone (opioid antagonist) can be life-saving — proactive availability is strongly recommended.
Class
Opioide
Pharmacological context
Mechanism
μ-opioid receptor agonism (preclinical evidence; noroxymorphone...
Short read on known pharmacology
Interactions
No curated pairs visible
Curated visible combinations
Risk theme
High Risk
Condensed from structured notes
Translation in progress
The German version has more complete content. This English page is being expanded; safety-critical risk and interaction sections may still appear while translation continues.
Newly emerging RC with high-potency warning signal — respiratory depression possible, no substance-specific human data.
Evidence confidence
Critical risk signals
Combination can be fatal; naloxone may be life-saving in opioid overdose.
SuspectedCritical combination — downer mix
Combination can be fatal; naloxone may be life-saving in opioid overdose.
Synapedia is actively monitoring this substance. Data is updated as new signals emerge.
Market signal: 5 mg pellets
Market signal: PHM is discussed as 5 mg pellets. This is not a dosing recommendation. For a poorly studied opioid-like RC, a marketed unit may already be too strong.
Scientific interpretation
Why is this substance flagged?
This substance is flagged because structural-chemical features indicate opioid-like μ-receptor activity. Combination with other CNS depressants can be life-threatening even at low amounts. No validated human data exist — the risk profile is entirely class-based.
N-Phenethyl substitution is pharmacologically relevant in opioid-like morphinan structures. Literature on N-phenethyl analogues of norhydromorphone shows substantial variation in μ-opioid receptor affinity, agonism/antagonism, and functional potency among related molecules. Minor changes to the N-phenethyl side chain can significantly alter activity.
For PHM, this means the structure provides a plausible warning signal for opioid-class risks but does not substitute for human data. No safe dose, duration of effect, or oxycodone/morphine equivalence can be derived from related in-vitro data.
This source provides structural-chemical SAR context — no human data on PHM.
Where does this assessment come from?
Known — structure-based
Derived from chemical class (morphinan opioid) and in-vitro data on structurally related compounds.
Suspected — class-based
Extrapolated from known opioid profile: μ-receptor agonism, respiratory depression, tolerance development.
Unknown — no human data
Pharmacokinetics, safe dose range, interaction profile and long-term effects in humans are not established.
Deep-dive intelligence
Recent Reddit and RC community discussions show that PHM / N-Phenethyl Noroxymorphone has been receiving significantly more attention. There are German and English-language threads, aggregation posts and first experience reports. Synapedia treats these as community signals, not verified human data.
Recurring signals
PHM is sometimes described as a 5 mg pellet or 5 mg pill — this is a declared product strength, not a dosing recommendation.
Some reports describe a pharma-opioid-like effect and draw subjective comparisons to other opioids.
Other reports are more cautious, describing less euphoria than expected.
Reports often include relevant confounders: opioid tolerance, benzodiazepine afterglow or other consumption contexts.
It remains unclear whether the described products were analytically confirmed and whether active ingredient distribution and purity are reliable.
These reports help identify current risks and user questions. However, they do not permit reliable conclusions about dose, duration, potency, re-dosing or comparability to other opioids.
Community reports on PHM are uncontrolled. It usually remains unclear:
For a newly emerging opioid-like RC, such uncertainties can be life-threatening. Synapedia therefore documents community signals but does not publish dose ranges or opioid equivalence.
Receptor Targets
Mechanism of Action
N-Phenethyl-Noroxymorphone (PHM) acts through the following pharmacological mechanisms:
Designations
Receptor Profile
The μ-opioid receptor (MOR) is a Gi-coupled GPCR involved in analgesia, euphoria and respiratory depression. It is the primary receptor target of most clinically used opioids.
Substance Fingerprint
Pharmacological profile based on receptor binding, mechanism of action, and substance class.
Synapedia Evidence
Effects & Pharmacology translation in progress
English prose is being expanded. The German version currently has more detail.
Risks & Harm Reduction translation in progress
English prose is being expanded. Safety-critical structured data may still be shown when available.
The risks listed may be incomplete. Especially for research chemicals and rare substances, available data is limited.
Community summaries. Not consumption guidance.
Entzug schlimmer als bei ODSMT, nach 10h geht der Horror los..
aber wesentlich potenter. Also vorsichtig forschen!!
Eine halbe Tablette davon kann schon zu viel sein!
Experiences + discussions about N-Phenethyl-Noroxymorphone (PHM)
No community discussions about N-Phenethyl-Noroxymorphone (PHM) yet. Start the first evidence-based discussion and share your experiences.
Based on substance class, receptors, mechanisms, and effect profile.
This information is for scientific and harm-reduction purposes only. It does not constitute medical advice.
Share a report, observation, or question about this substance. Entries are reviewed before publication and marked as unverified community signals.
These entries are submitted by users and are not verified. They may contain subjective experiences, observations, source leads, or corrections. They do not replace scientific data and are not consumption advice.
Help improve the evidence picture — for emerging RCs, reviewed community signals are especially valuable.
For emerging RCs, reports are reviewed especially cautiously. Claims about identity, strength, effects, and duration remain unverified.
The signal hub collects approved risk signals, experience reports and source leads by relevance.